Companies · Pharma

MatrubialsSummer 2021Active

Davis · CA, USA · Pharma · founded 2021 · https://matrubials.com/

Diligence memoA one-page analyst read on Matrubials — recommendation, valuation, rhythm, risks.
Total raised · real
0
Rounds
Latest step-up
Top 85%
Sector rank · raised
Latest stage · inferred

Matrubials: limited disclosed financing to assess.

Synthesized from the figures below est. — every claim rests on a number shown on this page.

Where it sits in Pharma

Matrubials is one of 310 Pharma companies tracked from Davis, CA, USA, on record since 2021. By capital raised it ranks in the long tail (ahead of 16% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

AI analyst read est. — model-extracted from this company's public description, not a verified fact. 30%

operates a technology-led product inferred from public copy

Grounded in: “You are a venture analyst

Developing milk-inspired therapeutics for infectious diseases

Matrubials is an anti-infectives company, focused on human milk peptides as therapeutics to address antimicrobial resistance and modern diseases. Currently the global rise in severe bacterial infections and the drying pipeline of effective treatments are burdensome for healthcare and economics. Sculpted by evolution, milk, first food for the newborn, provides an exemplary solution to address the nutritive and protective challenges an infant is faced with. The anti-pathogenic molecules from milk can be developed into therapeutics geared towards all-age diseases. Our first indication is bacterial vaginosis, a bacterial dysbiosis related inflammation that results in recurrent infections, disruption of homeostasis and long-term clinical complications in women of reproductive age, including but not limited to preterm births, fertility issues and increased rates of STDs. Our next inflection point is the evaluation of rapidly acting and selective candidate peptides in pre-clinical host impact and early safety studies, which can aid clinical and portfolio development towards topical applications.

AI-powered Drug DiscoveryTherapeuticsWomen's Healthpharma
Find Matrubials online

As reported in public records reported — not modeled.

US
Jurisdiction
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

No round amounts on record to chart.

Financing ladder & sequence gaps

No staged rounds to sequence.

Modeled valuation trajectory
Base estimate est.
Conservative case
Upside case
Modeled post-money

Round size and date are reported; the stage label is inferred from round size. Valuation is modeled from stage benchmarks. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Financing rhythm
Avg between rounds
Capital velocity
On record since
First round
0
Rounds on file
How it compares to the market

Benchmarked against 310 companies in Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages)
This company
Sector median$6.4M
Modeled value — vs sector median (estimate, all stages)
This company
Sector median$62.5M

Raised more than 16% of sector peers (real $). Modeled value above 16% of peers (estimate).

Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
No rounds recorded.
Intelligence
Modeled next raise
Modeled next size est.
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Registry & provenance

Matrubials is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
1200 Pharma LLCPharmaSeries A$14.1M$13.2Msame sector
A28 Therapeutics, Inc.PharmaSeed$1.9M$31.6Msame sector
AbInitio BioPharmasame sector
Acanna Therapeutics, Inc.PharmaPre-Seed$1.0M$16.0Msame sector
Advanced Cardiac Therapeutics IncPharmaSeries C$64.1M$1.6Bsame sector
ADvantage Therapeutics, Inc.PharmaSeries A$19.0M$111.2Msame sector
AeroRx Therapeutics, Inc.PharmaSeries A$10.4M$30.7Msame sector
Affect Therapeutics, Inc.PharmaSeries B$24.6M$232.4Msame sector
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Evolvere BioSciences
Making Next-Generation Antibiotics that Outpace Bacterial Evolution
Biotech73%
Promakhos Therapeutics Inc.
A therapeutics platform for curing inflammatory disorders
BiotechnologySeed$67.8M73%
Mati Therapeutics Inc.BiotechnologySeries A$28.3M73%
ImmunityBio, Inc.
We're dedicated to defeating cancer with therapies that target disease, not immune systems. Find our investigational immunotherapy and cell therapy products.
BiotechnologyGrowth/Late$7.8B72%
Microbion CorpPharmaceuticalsSeries B$328.6M72%
Nabla Bio
We use AI to design antibodies for intractable diseases
Biotech72%
SFA Therapeutics
Regulating the immune system to block cancer & autoimmune diseases
Biotech72%
ImmunoMolecular Therapeutics, Inc.BiotechnologySeries A$215.5M72%
Frequently asked
What does Matrubials do and where is it based?
Matrubials operates in the Pharma sector, based in Davis, CA, USA. Developing milk-inspired therapeutics for infectious diseases
Explore related

See where Matrubials sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Matrubials, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.